Molecular Internal Medicine

Endothelin Science

Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018


In Memoriam: Sidney George Shaw, DPhil (1948-2017)
M. Barton, H. J. Little, R.D. Vaughn-Jones, S. Daniels, M.R. Dashwood, M.R. Dashwood, J.C. Tsui.
Physiol Res 67 (Suppl. 1) S-27-S35, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018


GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016



Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015


Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014


In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014


25 Years of endothelin research: the next generation
N. Emoto, N. Vignon-Zellweger, R.A. Lopes, J. Cacioppo, L. Debiens, D. Kamato, T. Leurgans,
R. Moorhouse, J. Straube, R. Wurm, S. Heiden, A. Ergul, M. Yanagisawa, M. Barton
Life Sci 118, 77-86, 2014


Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014


Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014


Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretalla, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci
118, 206-212, 2014


Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz

Life Sci 118, 226-231, 2014


Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura

Cardiol Rev 24, 124-220, 2013


Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013


Themed section: Endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013


Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T. Masaki

Life Sci 91, 449-451, 2012


The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
M. Barton, A.P. Davenport
Life Sci 91, 462-465, 2012


The First Tomoh Masaki Award (2011)
M. Barton, N. Emoto, T. Miyauchi

Life Sci 91, 466-469, 2012


Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton

Life Sci 91, 528-539, 2012


The future of endothelin research: scientific mentoring and beyond
M. Barton, D.M. Pollock

Life Sci 91, 470-474, 2012


GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz

Life Sci 91, 623-627, 2012


Endothelin and the podocyte
Matthias Barton, Pierre-Louis Tharaux

Clin Kidney J 5, 17-27, 2012


Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
Matthias Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012


Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
Matthias Barton, Oliver Baretella, Matthias R. Meyer
Br J Pharmacol 165, 591-602, 2012


Endothelin antagonists in clinical trials: Lessons learned
Matthias Barton, Donald E. Kohan
Contrib Nephrol 172, 255-260, 2011


Endothelin and podocyte injury in chronic kidney disease
Cecile Fligny, Matthias Barton, Pierre-Louis Tharaux

Contrib Nephrol 172, 120-138, 2011


Endothelin antagonism and reversal of proteinuric renal disease in humans
Matthias Barton

Contrib Nephrol 172, 210-222, 2011


The discovery of endothelium-dependent contraction: the Legacy of Paul M. Vanhoutte
Matthias Barton

Pharmacol Res 63, 455-462, 2011


Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
Matthias Barton
Biochim Biophys Acta 1802, 1203-1213, 2010


Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
Matthias Barton, Philipp C. Nett, Kerstin Amann, Mauro M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010


Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
Matthias R. Meyer, Oliver Baretella, Eric R. Prossnitz, Matthias Barton
Pharmacology 86, 58-64, 2010


Reversal of proteinuric renal disease and the emerging role of endothelin
Matthias. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008


Endothelin - Twenty years from discovery to therapy
Matthias Barton, Masashi Yanagisawa
Can J Physiol Pharmacol 86, 485-498, 2008


Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
Alexa L. Mundy, Elvira Haas, Indranil Bhattacharya, Corinne C. Widmer, Martin Kretz, Regina Hofmann-Lehmann, Roberta Minotti,
Matthias Barton
Cardiovasc Res 73, 368-375, 2007


Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
Alexa L. Mundy, Elvira Haas, Indranil Bhattacharya, Corinne C. Widmer, Martin Kretz, Karin Baumann,
Matthias Barton
Am J Physiol Regul Integr Comp Physiol  293, R2218-R2224, 2007

Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine.
Philipp C. Nett, Mauro M. Teixeira, Daniel Candinas,
Matthias Barton
Recent Pat Cardiovasc Drug Discov 1, 233-244, 2006


Role of endothelin receptors for renal protection and survival in hypertension. Waiting for clinical trials
Matthias Barton, John J. Mullins, Matthew A. Bailey, Matthias Kretzler
Hypertension 48, 834-837, 2006


Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
Tobias Traupe, Jana Ortmann, Elvia Haas, Klaus Münter, Niranjan. Parekh, Regina Hofmann-Lehmann, Karin Baumann,
Matthias Barton
J Cardiovasc Pharmacol 47, 456-462, 2006


Beneficial cardiovascular effects of endothelin ETA receptor blockade in established long-term heart failure after myocardial infarction
Diana Vetter, Sidney G. Shaw, Ralf P. Brandes, Klaus Münter, Wilhelm Vetter,
Matthias Barton
Exp Biol Med (Maywood) 231, 857-60, 2006


Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection
Thomas Lattmann, Jana Ortmann, Sibylle Horber, Sidney G. Shaw, Marc Hein,
Matthias Barton
Exp Biol Med (Maywood) 231, 899-901, 2006


Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins
Gregor Muller, Rusan A. Catar, Bernd Niemann,
Matthias Barton, Lilla Knels, Martina Wendel, Henning Morawietz
Exp Biol Med (Maywood) 231, 766-771, 2006


Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus
Philipp C. Nett, Jana Ortmann, Jennifer Celeiro, Elvira Haas, Regina Hofmann-Lehmann, Luigi Tornillo, Luigi M. Terraciano,
Matthias Barton
Life Sci 78, 2213-2218, 2006


Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
Jana Ortmann, Philipp C. Nett, Jennifer Celeiro, Regina Hofmann-Lehmann, Luigi Tornillo, Luigi M. Terraciano,
Matthias Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006


Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence
for endothelin release by pancreatic islet β-cells.

Jana Ortmann, P.C. Nett, J. Celeiro, Tobias Traupe, Luigi Tornillo, Regina Hofmann-Lehmann, Elvira Haas, Beat Frank, Luigi M. Terraciano,
Matthias Barton
Biochem Biophys Res Commun 334, 689-695, 2005


Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells
Bernd Niemann, Susanne Rohrbach, Rusan A. Catar, Gregor Muller,
Matthias Barton, Henning Morawietz
Biochem Biophys Res Commun 334, 747-753, 2005


Endothelin in the microvasculature
Matthias Barton
In: Microvascular Research: Biology and Pathobiology (D. Shepro, Ed.), Academic Press, San Diego, 5-12, 2005


Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection:
role of endothelin receptor signaling

Thomas Lattmann, Marc Hein, Sibylle Horber, Jana Ortmann, Mauro M. Teixeira, Danielle G. Souza, Elvira Haas, Luigi Tornillo, Klaus Münter, Wilhelm Vetter,
Matthias Barton
Am J Transplant 5, 1042-1049, 2005


Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
Thomas Lattmann, Sidney Shaw, Klaus Münter, Wilhelm Vetter,
Matthias Barton
Biochem Biophys Res Commun 327, 234-241, 2005


Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes
Tobias Traupe, Matthias Lang, Jana Ortmann, Mario Keller, Eva Fojtu, Wilhelm Vetter,
Matthias Barton
J Cardiovasc Pharmacol 44, S113-S116, 2004


Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice
Jana Ortmann, Tobias Traupe, Philipp C. Nett, Jennifer Celeiro, Regina Hofmann-Lehmann, Melanie Lange, Wilhelm Vetter,
Matthias Barton
J Cardiovasc Pharmacol 44, S105-S108, 2004


Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
Jana Ortmann, Kerstin Amann, Ralf P. Brandes, Matthias Kretzler, Klaus Münter, Niranjan Parekh, Tobias Traupe, Melanie Lange, Thomas Lattmann,
Matthias Barton
Hypertension 44, 974-981, 2004


In-vivo interactions of nitric oxide and endothelin
Thomas Lattmann, Wilhelm Vetter,
Matthias Barton
J Hypertens 22, 1839-1840, 2004


Protective Role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats
Elisabeth R.S. Camargos, Lamara L.V. Rocha, Milene A. Rachid, Aalvair P. Almeida, Anderson J. Ferreira, Antonio L. Teixeira-Jr, Egler Chiari, Matthias Barton, Mauro M. Teixeira, Conceicao R.S. Machado
Microbes Infect 6, 650-656, 2004


Endothelin, hypercholesterolemia and atherosclerosis
Matthias Barton, Tobias Traupe, Christian C. Haudenschild
Coron Artery Dis 14, 477-490, 2003


Role of endothelin during experimental Trypanosoma cruzi infection in rats
Elisabth R.S. Camargos, Conceicao R.S. Machado, Antonio L. Teixeira-Jr, Lamara L.V. Rocha, Anderson J. Ferreira, Alvair P. Almeida,
Matthias Barton, Mauro M.Teixeira
Clin Sci (Lond) 103(S), 64S-67S, 2002


Increased expression of endothelin-converting enzyme-1 in failing human myocardium
Henning Morawietz, Winfried Goettsch, Marten Szibor, Matthias Barton, Sidney Shaw, Kavous Hakim, Hans-Reinhard Zerkowski, Jürgen Holtz
Clin Sci (Lond) 103(S), 237S-240S, 2002


Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
Livius V. d'Uscio,
Matthias Barton, Sidney Shaw, Thomas F. Luscher
Cardiovasc Res 53, 487-495, 2002


Endothelin receptor blockade and nitric oxide bioactivity
Matthias Barton, B. Glodny
Cardiovasc Res 52, 161-163, 2001


The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
Matthias Barton, Wolfgang Kiowski
Curr Hypertens Rep 3, 322-330, 2001


Endothelin and cardiac arrhythmias: do endothelin antagonists have therapeutic potential as antiarrhythmic drugs?
Firat Duru,
Matthias Barton, Thomas Luscher, Reto Candinas
Cardiovasc Res 49, 272-280, 2001


Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
Winfried Goettsch, Thomas Lattmann, Kerstin Amann, Marten Szibor, Henning Morawietz, Klaus Münter, Sylvana P. Müller, Sidney Shaw, Matthias Barton
Biochem Biophys Res Commun 280, 908-13, 2001


Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three dimensional mapping
Firat Duru,
Matthias Barton, Reto Candinas
Cardiovasc Res 46, 604-605, 2000


Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease
Matthias Barton, Thomas Lattmann, Livius V. d'Uscio, Thomas Luscher, Sidney Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000


Endothelin regulates angiotensin-converting enzyme in the mouse kidney
Matthias Barton, Renata Carmona, Jose E. Krieger, Winfried Göettsch, Henning Morawietz, Livius V. d'Uscio, Thomas Lattmann, Thomas Luscher, Sidney Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000


Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms
of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis

Matthias Barton, Ingrid Vos, Sidney Shaw, Peter Boer, Livius V. d'Uscio, Hermann-Josef. Gröne, Ton J. Rabelink, Thomas Lattmann, Pierre Moreau, Thomas Luscher
J Am Soc Nephrol 11, 835-846, 2000


Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade
M. Burkhardt, Matthias Barton, Sidney G. Shaw
J Hypertens 18, 273-279, 2000


Endothelin and endothelin antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
Thomas Luscher,
Matthias Barton
Circulation 102, 2434-2440, 2000


Endothelin und Atherosklerose. Kausale Bedeutung und therapeutische Implikationen
Matthias Barton
Kardiovask Med 3, 13-18, 2000


Endothelin in atherosclerosis: importance of risk factors and therapeutic implications
Livius V. d'Uscio, Matthias Barton, Sidney Shaw, Thomas Luscher
J Cardiovasc Pharmacol 35 (4 suppl 2), S55-S59, 2000


Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics
Matthias Barton
Curr Hypertens Reports 2, 84-91, 2000


Endothelin antagonists for hypertension and renal disease
Matthias Barton, Thomas Luscher
Curr Opin Nephrol Hypertens 8, 549-556, 1999


Endothelin in heart failure
Gabor Sutsch, Matthias Barton
Curr Hypertens Reports 1, 62-68, 1999


Endothelial dysfunction in acute renal faiulre: role of circulating and tissue endothelin-1
Frank Ruschitzka, Sidney Shaw, Daniel Gygi, Georg Noll, Matthias Barton, Thomas Luscher
J Am Soc Nephrol 10, 953-962, 1999


Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
Matthias Barton, Christian C. Haudenschild, Livius V. d`Uscio, Sidney Shaw, Klaus Münter, Thomas Luscher
Proc Natl Acad Sci U.S.A. 95, 14367-14372, 1998


Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase. Role of blood pressure and endothelial function
Livius V. d`Uscio, Sidney Shaw, Matthias Barton, Thomas Luscher
Hypertension 31, 1305-1310, 1998


Differential modulation of the renal myocardial endothelin system by angiotensin II in vivo: effects of chronic selective ETA receptor blockade
Matthias Barton, Sidney Shaw, Livius V. d'Uscio, Pierre Moreau, Thomas Luscher
J Cardiovasc Pharmacol 31 (Suppl 1), S265-S268, 1998


ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
Matthias Barton, Livius V. d`Uscio, Sidney Shaw, Peter Meyer, Pierre Moreau, and Thomas Luscher
Hypertension 31, 499-504, 1998


Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade
Livius V. d'Uscio, Matthias Barton, Sidney Shaw, Pierre Moreau, Thomas Luscher
Hypertension 30, 905-911, 1997


Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist
Pierre Moreau, Livius V. d'Uscio, Sidney Shaw, Hiroyuki Takase, Matthias Barton, Thomas Luscher
Circulation 96, 1593-1597, 1997 (Link)


Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
Livius V. d`Uscio, Pierre Moreau, Sidney Shaw, Hiroyuki Takase, Matthias Barton, Thomas Luscher
Hypertension 29, 435-441, 1997                                     


Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation
Matthias Barton, Sidney Shaw, Livius V. d`Uscio, Pierre Moreau, Thomas Luscher
Biochem Biophys Res Commun 238, 861-865, 1997